Avanir Pharmaceuticals Inc (AVNR) financial statements (2021 and earlier)

Company profile

Business Address 20 ENTERPRISE
ALISO VIEJO, CA 92656
State of Incorp. DE
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2014
Q4
6/30/2014
Q3
3/31/2014
Q2
12/31/2013
Q1
9/30/2013
Q4
6/30/2013
Q3
3/31/2013
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments272855444555568
Cash and cash equivalents272855444555568
Receivables2321174131210
Inventory, net of allowances, customer advances and progress billings1111110
Inventory1111110
Prepaid expense222211 
Prepaid expense and other current assets3
Other current assets200011 
Other undisclosed current assets1446111
Total current assets:3011137856727081
Noncurrent Assets
Inventory, Noncurrent1111111
Property, plant and equipment4333222
Restricted cash and investments1111111
Other noncurrent assets111111 
Prepaid expense and other noncurrent assets1
Total noncurrent assets:6665445
TOTAL ASSETS:3071188461767586
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities32252721261113
Accounts payable75104668
Accrued liabilities1514111212  
Employee-related liabilities10765865
Debt 111111858
Deferred revenue and credits  01   
Other undisclosed current liabilities    11111
Total current liabilities:32373832352731
Noncurrent Liabilities
Long-term debt and lease obligation 131619212421
Long-term debt, excluding current maturities 131619212421
Liabilities, other than long-term debt22221  
Other liabilities22221  
Other undisclosed noncurrent liabilities     11
Total noncurrent liabilities:2151820232523
Total liabilities:34525652585254
Stockholders' equity
Stockholders' equity attributable to parent27367289182232
Common stock0000000
Additional paid in capital824604552520519487486
Accumulated deficit(551)(537)(524)(511)(501)(465)(454)
Total stockholders' equity:27367289182232
TOTAL LIABILITIES AND EQUITY:3071188461767586

Income statement (P&L) ($ in millions)

9/30/2014
Q4
6/30/2014
Q3
3/31/2014
Q2
12/31/2013
Q1
9/30/2013
Q4
6/30/2013
Q3
3/31/2013
Q2
Revenues
(Revenue, Net)
33292727222017
Cost of revenue
(Cost of Goods and Services Sold)
1(2)(1)(1)(1)(1)(1)
Gross profit:34272625201916
Operating expenses(45)(41)(39)(37)(56)(30)(33)
Other undisclosed operating income (loss)(1)211111
Operating loss:(13)(12)(12)(10)(34)(10)(15)
Nonoperating income (expense)00(0)0000
Investment income, nonoperating0000000
Other nonoperating income (expense)0 (0)0 (0)0
Interest and debt expense(1)(1)(1)(1)(1)(1)(1)
Loss from continuing operations before income taxes:(14)(13)(13)(11)(35)(11)(17)
Other undisclosed loss from continuing operations(0)   (0)  
Net loss available to common stockholders, diluted:(14)(13)(13)(11)(35)(11)(17)

Comprehensive Income ($ in millions)

9/30/2014
Q4
6/30/2014
Q3
3/31/2014
Q2
12/31/2013
Q1
9/30/2013
Q4
6/30/2013
Q3
3/31/2013
Q2
Net loss:(14)(13)(13)(11)(35)(11)(17)
Comprehensive loss, net of tax, attributable to parent:(14)(13)(13)(11)(35)(11)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: